Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Allergan Plc (AGN)

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,441,356
  • Shares Outstanding, K 327,802
  • Annual Sales, $ 15,787 M
  • Annual Income, $ -5,096,400 K
  • 60-Month Beta 1.63
  • Price/Sales 3.44
  • Price/Cash Flow 4.48
  • Price/Book 0.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 4.28
  • Number of Estimates 11
  • High Estimate 4.36
  • Low Estimate 4.20
  • Prior Year 4.42
  • Growth Rate Est. (year over year) -3.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.27 +44.41%
on 06/17/19
170.19 -3.04%
on 07/02/19
+49.10 (+42.35%)
since 06/14/19
3-Month
114.27 +44.41%
on 06/17/19
170.19 -3.04%
on 07/02/19
+19.60 (+13.48%)
since 04/16/19
52-Week
114.27 +44.41%
on 06/17/19
197.00 -16.24%
on 10/03/18
-10.65 (-6.06%)
since 07/16/18

Most Recent Stories

More News
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

AZN : 40.16 (-0.15%)
LLY : 108.45 (-0.02%)
AGN : 164.91 (-0.70%)
ALKS : 23.65 (+1.33%)
Anal Fissure Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2018 To 2023

Anal Fissure Treatment Market Research Report: by Treatment Type (Medication, Surgery), by Route of Administration (Oral, Topical), by End-user (Hospitals & Clinics, Research & Academic Institutes), and...

VRX.TO : 30.80 (-3.33%)
BAYRY : 16.5800 (-2.98%)
ABT : 82.98 (-0.99%)
AGN : 164.91 (-0.70%)
ESALF : 60.0000 (+2.21%)
GSK : 41.12 (+0.54%)
Allergan Plc Has Returned 27.5% Since SmarTrend Recommendation (AGN)

SmarTrend identified an Uptrend for Allergan Plc (NYSE:AGN) on June 20th, 2019 at $130.21. In approximately 4 weeks, Allergan Plc has returned 27.55% as of today's recent price of $166.08.

AGN : 164.91 (-0.70%)
Investor Rights Alert: Halper Sadeh LLP Continues Investigating Whether the Sale of These Companies is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - DFRG, RTEC, PCMI, AGN

Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies:

RTEC : 26.88 (-1.25%)
DFRG : 7.93 (-0.13%)
AGN : 164.91 (-0.70%)
PCMI : 34.85 (-0.34%)
Government of Quebec Now Covers a More Effective Emergency Contraceptive Pill

ella(®) (ulipristal acetate) now reimbursed in Quebec

AGN : 164.91 (-0.70%)
J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?

J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.

MRK : 80.92 (-0.05%)
JNJ : 132.83 (-1.40%)
AGN : 164.91 (-0.70%)
ABBV : 69.51 (-1.08%)
Anal Fissure Treatment is expected to reach the valuation of USD 2,526.5 million by the year 2023, by growing at a CAGR of 7.6% during the forecast period (2018- 2023)

Anal Fissure Treatment Market Research Report: by Treatment Type (Medication, Surgery), by Route of Administration (Oral, Topical), by End-user (Hospitals & Clinics, Research & Academic Institutes), and...

VRX.TO : 30.80 (-3.33%)
BAYRY : 16.5800 (-2.98%)
ABT : 82.98 (-0.99%)
AGN : 164.91 (-0.70%)
ESALF : 60.0000 (+2.21%)
GSK : 41.12 (+0.54%)
Allergan (AGN) Gains But Lags Market: What You Should Know

Allergan (AGN) closed at $166.70 in the latest trading session, marking a +0.15% move from the prior day.

AGN : 164.91 (-0.70%)
Global Inflammatory Bowel Disease Treatment Market Size, Share, Trends and Growth Until the End of 2026

VRX.TO : 30.80 (-3.33%)
AGN : 164.91 (-0.70%)
NVS : 88.74 (-0.59%)
SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
ABBV : 69.51 (-1.08%)
PFE : 42.54 (-0.49%)
Will Patent Woes Boost Pharma Stock Megamergers Further?

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

CELG : 91.76 (+0.02%)
AGN : 164.91 (-0.70%)
ABBV : 69.51 (-1.08%)
GILD : 67.06 (-1.48%)
AMGN : 176.51 (+0.22%)
BMY : 44.41 (+0.50%)
BIIB : 232.50 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators mostly agree with the trend.

See More Share

Trade AGN with:

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

2nd Resistance Point 168.20
1st Resistance Point 167.14
Last Price 164.91
1st Support Level 165.09
2nd Support Level 164.10

See More

52-Week High 197.00
Fibonacci 61.8% 165.40
Last Price 164.91
Fibonacci 50% 155.63
Fibonacci 38.2% 145.87
52-Week Low 114.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar